title: Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
abstract: OBJECTIVE
  To compare the treatment outcome of surgery alone with that of surgery followed by adjuvant chemoradiotherapy (CRT) for duodenal cancer.
  
  
  METHODS
  Between January 1991 and December 2002, 24 patients with duodenal cancer underwent pancreaticoduodenectomy. There were 14 males and 10 females, and median age was 61 years (range, 33-75). Nine patients received adjuvant CRT, and 15 did not. Postoperative radiotherapy was delivered up to 40 Gy at 2 Gy/fraction with a 2-week planned rest. Intravenous 5-fluorouracil (500 mg/m/d) was given on days 1 to 3 of each split course. Median follow-up period was 32 months (range, 5-170).
  
  
  RESULTS
  Nodal stage and stage group were more advanced in CRT (+) group (P=0.0894 and 0.0361, respectively). However, other patient and tumor characteristics were similar in each group. Five-year overall survival rates of CRT (-) and CRT (+) group were 47% and 30%, respectively (P=0.3799). Five-year locoregional relapse-free survival rates of CRT (-) and CRT (+) group were 64% and 80%, respectively (P=0.4188). On multivariate analysis, patients treated with adjuvant CRT had better locoregional relapse-free survival with borderline significance (P=0.0750). No patient suffered grade 3 or higher toxicity during CRT.
  
  
  CONCLUSIONS
  Adjuvant CRT is feasible and may enhance locoregional control in advanced-staged duodenal cancer after curative resection.
authors.affiliation: Departments of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
authors.forename: Kyubo
authors.initials: K
authors.lastname: Kim
authors.forename: Eui Kyu
authors.initials: EK
authors.lastname: Chie
authors.forename: Jin-Young
authors.initials: JY
authors.lastname: Jang
authors.forename: Sun Whe
authors.initials: SW
authors.lastname: Kim
authors.forename: Do-Youn
authors.initials: DY
authors.lastname: Oh
authors.forename: Seock-Ah
authors.initials: SA
authors.lastname: Im
authors.forename: Tae-You
authors.initials: TY
authors.lastname: Kim
authors.forename: Yung-Jue
authors.initials: YJ
authors.lastname: Bang
authors.forename: Sung W
authors.initials: SW
authors.lastname: Ha
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D002288:Adenocarcinoma, Mucinous / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004379:Duodenal Neoplasms / Q000473:pathology* / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D010179:Pancreas / Q000473:pathology; D016577:Pancreaticoduodenectomy; D016016:Proportional Hazards Models; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D005472:Fluorouracil